Investing.com — 年收入为1936万美元的生物制药公司Evofem Biosciences, Inc.已与Windtree Therapeutics, Inc.修订了关于非激素避孕产品PHEXXI®的制造和供应协议。这项修正案日期为2025年3月28日，对2025年3月20日建立的原许可和供应协议条款进行了完善。根据 InvestingPro ...

Evofem Biosciences (EVFM) announced that it has entered into a License and Supply Agreement with Windtree Therapeutics (WINT), under which ...

Already this year, policyholders across the country have filed claims for damages related to wind, hail, wildfires, and water. However, these causes of loss, when attributed to HVAC and refrigeration ...

Evofem Biosciences, Inc. (OTCQB: EVFM) (Evofem or the Company) today announced that it has entered into a License and Supply ...

WARRINGTON, Pa., March 24, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating biotech ...

Women's health innovator Evofem Biosciences, Inc. , today announced financial results for the fourth quarter and year ended December 31, 2024. Highlights ...

Why didn’t analysts share the same fear that gripped investors about Sarepta stock? One reason is the known risk of acute liver injury associated with adeno-associated virus vector (AAV)-based gene ...

Windtree Therapeutics, Inc. (NasdaqCM: WINT) has entered a License and Supply Agreement with Evofem Biosciences, Inc. (OTCQB: ...

(NASDAQ:WINT), a biotechnology firm, has announced a License and Supply Agreement with Evofem Biosciences, Inc. (OTCQB:EVFM) to become the sourcing partner for the contraceptive vaginal gel, PHEXXI®.

(OTCQB: EVFM) for one of Evofem’s FDA-approved products -- PHEXXI ® (lactic acid, citric acid and potassium bitartrate). The product is a first-in-class hormone-free, on-demand prescription ...

A Pennsylvania-based biotech firm is already off to the races during Thursday’s premarket hours after the company announced that it has entered into a license and supply agreement to become a ...